Summary: The Centers for Medicare & Medicaid Services modified its coverage policy on cytotoxic food testing, effective May 15, 2026. Here's what billing teams need to know before claims go out the door.
CMS cytotoxic food test coverage policy has been a contested topic for decades, and this 2026 modification keeps it squarely in that tradition. The Centers for Medicare & Medicaid Services has long treated cytotoxic food testing — sometimes called the Bryan test, leukocytotoxic test, or ALCAT test — as unproven and not eligible for Medicare reimbursement. This policy update reinforces that position. The policy does not list specific CPT or HCPCS codes in the available documentation, but that doesn't mean your billing team gets a pass. If you're billing for any food sensitivity or cytotoxic testing under Medicare, this change demands your attention before May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Cytotoxic Food Tests |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium — high denial risk for practices billing food sensitivity testing under Medicare |
| Specialties Affected | Allergy/Immunology, Internal Medicine, Integrative Medicine, Functional Medicine, Gastroenterology |
| Key Action | Audit any cytotoxic or food sensitivity test claims billed to Medicare and confirm medical necessity documentation before May 15, 2026 |
CMS Cytotoxic Food Test Coverage Criteria and Medical Necessity Requirements 2026
The core of this policy is straightforward: CMS does not consider cytotoxic food testing to meet the standard of medical necessity for Medicare coverage. This has been the agency's position for years, and the 2026 modification does not reverse it.
Cytotoxic food tests — including the ALCAT test, the Bryan test, and similar leukocytotoxic assays — claim to identify food sensitivities by exposing white blood cells to food antigens and measuring cellular changes. The clinical community has not validated these tests through rigorous, reproducible studies. CMS agrees, and that's the foundation of its coverage policy.
Under Medicare billing guidelines, a service must be "reasonable and necessary" to qualify for reimbursement. CMS has determined that cytotoxic food tests don't clear that bar. The agency views the clinical evidence as insufficient to support routine use. That means any claim for cytotoxic testing billed to a Medicare patient faces a high probability of claim denial.
This matters especially for practices in integrative or functional medicine, where food sensitivity panels are commonly ordered. Patients may want these tests. Physicians may believe they're clinically useful. But Medicare's position hasn't softened, and this 2026 modification signals the agency is actively maintaining — not relaxing — its stance.
If your practice bills Medicare for food sensitivity testing of any kind, talk to your compliance officer before May 15, 2026. The distinction between covered allergy testing and non-covered cytotoxic testing is exactly the kind of line that gets blurry in billing systems and charge capture workflows.
CMS Cytotoxic Food Test Exclusions and Non-Covered Indications
CMS treats cytotoxic food testing as investigational and not medically necessary. This is not a gray area with a narrow covered subset — the entire category of cytotoxic food testing is excluded from Medicare coverage.
The tests excluded under this coverage policy include any variation of the leukocytotoxic test, including branded versions marketed under names like ALCAT or the Bryan test. The exclusion applies regardless of the clinical indication cited on the claim.
Ordering these tests because a patient presents with chronic gastrointestinal symptoms, fatigue, or suspected food intolerance does not make them covered. Documenting a clinical rationale in the chart doesn't override the coverage policy. CMS's position is that the tests themselves lack sufficient clinical validity — not that the indications are wrong.
This is an important distinction for billing teams to understand. Prior authorization won't help here, because the service is non-covered by policy — not just administratively unprocessed. There's no prior auth pathway that unlocks reimbursement for a test CMS has categorically excluded.
If a patient wants cytotoxic food testing and you're going to provide it, an Advance Beneficiary Notice of Noncoverage (ABN) is your protection. The ABN shifts financial liability to the patient. Without it, your practice absorbs the cost if the patient disputes the charge after a claim denial.
Coverage Indications at a Glance
The policy does not provide indication-specific coverage data with associated codes. Based on the policy title and CMS's longstanding position on cytotoxic food testing, the coverage status by indication is as follows:
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Cytotoxic food testing (any indication) | Not Covered | Not specified in policy data | CMS considers these tests investigational and not medically necessary |
| Bryan test / leukocytotoxic test | Not Covered | Not specified in policy data | Branded and unbranded versions excluded |
| ALCAT test | Not Covered | Not specified in policy data | Falls under cytotoxic food test exclusion |
| Food sensitivity panels using cytotoxic methodology | Not Covered | Not specified in policy data | Methodology, not indication, drives the exclusion |
CMS Cytotoxic Food Test Billing Guidelines and Action Items 2026
This is where the rubber meets the road for your billing team. The effective date of May 15, 2026 gives you a hard deadline to get your house in order.
| # | Action Item |
|---|---|
| 1 | Audit your charge master and charge capture for any food sensitivity or cytotoxic testing codes billed to Medicare patients. Pull claims from the last 12 months. If your practice has been billing these tests to Medicare — even occasionally — quantify the exposure now. Denied claims, underpaid claims, and potential overpayments are all on the table. |
| 2 | Identify which tests in your order workflow fall under the cytotoxic food test category. Branded tests like ALCAT may not be labeled "cytotoxic" in your EHR or lab interface. Work with your lab partners to confirm which panels use cytotoxic methodology. This is a clinical and billing conversation — loop in your medical director. |
| 3 | Issue ABNs for any Medicare patient who wants cytotoxic food testing before the test is performed. The ABN must be signed before the service, not after. Post-service ABNs are not valid. If your front desk or clinical staff isn't clear on this process, retrain them before May 15, 2026. |
| 4 | Review your LCD (Local Coverage Determination) landscape for allergy testing codes. Standard allergy testing — skin testing, specific IgE blood tests — is a separate category with its own coverage criteria. Make sure your billing team isn't inadvertently coding cytotoxic tests using covered allergy testing codes. That's the kind of mismatch that triggers a Medicare Administrative Contractor audit. |
| 5 | Update your payer policy documentation for staff training. Your billing guidelines for CMS should reflect the May 15, 2026 effective date and include clear language that cytotoxic food tests are non-covered under Medicare. Document this in your compliance records. |
| 6 | If you're uncertain how this policy applies to your specific test menu or patient mix, contact your Medicare Administrative Contractor. MACs have jurisdiction over local coverage determinations and can clarify how the national policy interacts with any LCD in your region. Don't assume your regional MAC has aligned exactly with the national CMS position without checking. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cytotoxic Food Tests Under CMS Policy
The policy document does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is important context, not a technicality.
When CMS excludes a testing category at the policy level without enumerating specific codes, it creates a billing interpretation challenge. Your billing team can't simply look up a code on a fee schedule and assume it's covered or excluded based on code status alone. The exclusion applies to the category of service — cytotoxic food testing — regardless of which code is used to represent it.
This means cytotoxic food testing billing requires judgment at the code level, not just a lookup. If a lab bills with a miscellaneous code or an unlisted procedure code, the claim still falls under this coverage policy if the underlying test is cytotoxic in methodology.
Talk to your compliance officer and your lab billing partner about how these tests are currently coded in your system. If there's ambiguity, get a formal opinion before May 15, 2026 — not after a claim denial triggers a review.
What This Means for Your Remittance Reviews
When CMS denies claims for non-covered services, the remittance advice typically carries a CO-50 or CO-177 denial reason code. If you're seeing those codes on food sensitivity or allergy-adjacent claims, pull the test descriptions and cross-reference them against this coverage policy. A pattern of CO-50 denials in this category is a compliance signal, not just a billing inconvenience.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.